Journal article
A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women
Helena Johansson, John A Kanis, Anders Oden, Eugene McCloskey, Roland D Chapurlat, Claus Christiansen, Steve R Cummings, Adolfo Diez-Perez, John A Eisman, Saeko Fujiwara, Claus-C Glueer, David Goltzman, Didier Hans, Kay-Tee Khaw, Marc-Antoine Krieg, Heikki Kroeger, Andrea Z LaCroix, Edith Lau, William D Leslie, Dan Mellstroem Show all
Journal of Bone and Mineral Research | WILEY | Published : 2014
DOI: 10.1002/jbmr.2017
Grants
Awarded by Medical Research Council UK
Awarded by Cancer Research UK
Awarded by DOE
Awarded by National Institute of Musculoskeletal and Skin Diseases
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Funding Acknowledgements
HJ was supported by an ESCEO-AMGEN Osteoporosis Fellowship Award. Amgen had no input into the analysis plan or in the writing of this report. The EPIC-Norfolk study is supported by the Medical Research Council UK (G0401527) and Cancer Research UK (8257). CPRD has received funding from the MHRA, Wellcome Trust, Medical Research Council, NIHR Health Technology Assessment program, Innovative Medicine Initiative, UK Department of Health, Technology Strategy Board, Seventh Framework Programme EU, various universities, contract research organizations, and pharmaceutical companies. The Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (www.tipharma.nl; includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. The AHS has been conducted at the Radiation Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan, which is a private, nonprofit foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Department of Energy (DOE), the latter in part through DOE Award DE-HS0000031 to the National Academy of Sciences. The ECOSAP Study was sponsored by Eli Lilly. The Rochester study was supported by the National Institute of Musculoskeletal and Skin Diseases (R01 AR27065), U.S. Public Health Service. CaMOS was funded by the Canadian Institutes for Health Research with contributions from pharmaceutical and other entities who made no contribution to the study design or execution.